Noticias de NERV_US

Noticias del mercado

Últimas noticias sobre NERV_US — 121 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: NERV_US ✕ 121 resultados
01/04/2026 NERV_US — The Manila Times
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
01/04/2026 NERV_US — Stock Titan
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity
31/03/2026 NERV_US — Intellectia AI
NERV Should I Buy

¿NERV es una compra, venta o retención hoy? Vea los últimos objetivos de precios de NERV, pronósticos de IA y calificaciones de expertos con Intellectia AI™.

31/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Announces First Patient Screened in
31/03/2026 NERV_US — Stock Titan
No approved drug exists for these schizophrenia symptoms; Minerva starts Phase 3
31/03/2026 NERV_US — Seeking Alpha
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia
31/03/2026 NERV_US — Stock Titan
NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered
31/03/2026 NERV_US — NTB Kommunikasjon
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
31/03/2026 NERV_US — Stock Titan
Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice
31/03/2026 NERV_US — Stock Titan
Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV)
31/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Announces First Patient Screened in
31/03/2026 NERV_US — Yahoo Finance
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
31/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Announces First Patient Screened in
26/03/2026 NERV_US — MarketBeat
Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV
25/03/2026 NERV_US — Investing News Network
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — Yahoo Finance
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Página 6 de 7

keyboard_arrow_up